Drug

Development

What We Do

Zikani has created an innovation engine with its proprietary TURBO-ZM platform, a sophisticated, replicable process that is generating an expanding library of novel small-molecule ribosome modulating agents (RMAs) with immense chemical diversity.

With increased specificity for a ribosome, the resulting small molecule modulators overcome the functional limitations of known Ribosome Modulations. These fully-synthetic RMAs are thus enabled to directly and specifically address underlying abnormalities in protein synthesis.

Our process enables identification of RMAs that are optimized for disease-level specificity, enhanced bioavailability, and superior long-term safety.